Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR18034 for Postoperative Pain in Total Knee Arthroplasty
NCT06509958Phase 2Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bupivacaine liposome in postoperative pain (3 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Area Under the Curve of NRS-A Pain Intensity Scores (0-72h). Started Aug 2024; status: terminated.
02
Drugs
bupivacaine liposome
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT06509958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06509958.